GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)

GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth at the upper end of the guidance ranges. However, it's hard to make a Buy case for it anymore as stock metrics like the forward P/E and dividend yield don't offer adequate support. While the company has maintained its long-term sales target, even that isn't encouraging enough from the stock price perspective as only limited price returns are foreseen.

The British pharmaceuticals company GSK (GSK) reported Q2 2026 and H1 2026 results earlier today, which show that it's on track to achieve the company's targets for full year 2026.